Serial entrepreneur Mike Grey is launching a biotech enterprise with $120 million in new funding to advance two investigational liver disease drugs-one of which he has worked to develop before.
Called Mirum Pharmaceuticals, the startup is developing a compound, maralixibat, to treat Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), genetic liver disorders that affect primarily children. Mirum plans to move maralixibat, its lead drug, into a Phase 3 trial next year.
Mirum’s clinical trial development will be based out of the Bay Area, where the company’s headquarters are set to be located. Grey and some of his former Lumena… Read more »
UNDERWRITERS AND PARTNERS